Lee Financial’s Beam Therapeutics BEAM Stock Holding History

Lee Financial’s Portfolio BEAM Stock Details BEAM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-17	Closed	-$1K	–	779
2021 Q4	$1K	Buy	+17	New	+$1.46K	﹤0.01%	820

Other funds holding BEAM

ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

MWG Management Road Town, Tortola, British Virgin Islands $81.3M AUM 2.28% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Lee Financial's BEAM Position: Q1 2022 in Review

Lee Financial sold out of Beam Therapeutics (BEAM) in Q1 2022, closing a stake of 17 shares — an estimated $1K sold.

Lee Financial first reported a position in BEAM in Q4 2021 and held it in 1 quarter. The position peaked at $1K in Q4 2021. 240 funds tracked by Wall St. Rank hold BEAM as of Q1 2022.

Lee Financial reported no remaining Beam Therapeutics position as of Q1 2022 after selling out during the quarter.
Lee Financial sold 17 Beam Therapeutics shares in Q1 2022, an estimated $1K.
Lee Financial first reported a position in Beam Therapeutics in Q4 2021 and held it in 1 quarter.
Lee Financial's Beam Therapeutics position peaked at $1K in Q4 2021.
240 funds tracked by Wall St. Rank held Beam Therapeutics as of Q1 2022.

Based on Lee Financial's 13F filing for Q1 2022, filed 11 May 2022.